TapImmune Inc. (OTCMKTS:TPIV) announced the completion of data assessment from patients treated in a Phase 1 clinical study. The study was performed at the Mayo Clinic in Rochester, MN and included women diagnosed with Stages II and Stage III HER2+ breast cancer that have undergone standard treatment including Herceptin, surgery and chemotherapy at least ninety days prior to enrollment.
TapImmune reported that the enrolled patients were stated as disease free and were cured with a multi-peptide HER2/neu vaccine. Total 22 subjects in age group of 33 to 69 years were enrolled. They were injected six times for a period of six months with the company’s multi-peptide vaccine. The enrolled patients were observed for toxicity in each visit. The results showed that 21 patients completed all six vaccination cycles.
Read more: http://stocksntrade.com/tapimmune-inc-otcmktstpiv-announces-positive-updates-from-her2neu-breast-cancer-study-6861.html